Related Experiment Video
Updated: Jul 31, 2025

Imaging the Intracellular Trafficking of APP with Photoactivatable GFP
Published on: October 17, 2015
PARP16-Mediated Stabilization of Amyloid Precursor Protein mRNA Exacerbates Alzheimer's Disease Pathogenesis
Jinghuan Wang1, Qianwen Cheng1, Yuyu Zhang1
1Pharmacophenomics Laboratory, Human Phenome Institute, Fudan University, Shanghai 201203, China.
Abstract:
The accumulation and deposition of beta-amyloid (Aβ) are key neuropathological hallmarks of Alzheimer's disease (AD). PARP16, a Poly(ADP-ribose) polymerase, is a known tail-anchored endoplasmic reticulum (ER) transmembrane protein that transduces ER stress during pathological processes. Here, we found that PARP16 was significantly increased in the hippocampi and cortices of APPswe/PS1dE9 (APP/PS1) mice and hippocampal neuronal HT22 cells exposed to Aβ, suggesting a positive correlation between the progression of AD pathology and the overexpression of PARP16. To define the effect of PARP16 on AD progression, adeno-associated virus mediated-PARP16 knockdown was used in APP/PS1 mice to investigate the role of PARP16 in spatial memory, amyloid burden, and neuroinflammation. Knockdown of PARP16 partly attenuated impaired spatial memory, as indicated by the Morris water maze test, and decreased amyloid deposition, neuronal apoptosis, and the production of inflammatory cytokines in the brains of APP/PS1 mice. In vitro experiments demonstrated that the knockdown of PARP16 expression rescued neuronal damage and ER stress triggered by Aβ. Furthermore, we discovered that intracellular PARP16 acts as an RNA-binding protein that regulates the mRNA stability of amyloid precursor protein (APP) and protects targeted APP from degradation, thereby increasing APP levels and AD pathology. Our findings revealed an unanticipated role of PARP16 in the pathogenesis of AD, and at least in part, its association with increased APP mRNA stability.
Insights
Poly(ADP-ribose) polymerase 16 (PARP16) overexpression correlates with Alzheimer's disease (AD) progression. Reducing PARP16 improved memory, decreased amyloid plaques, and lessened neuroinflammation in AD mouse models.
Area of Science:
- Neuroscience
- Molecular Biology
- Pathology
Background:
- Alzheimer's disease (AD) is characterized by beta-amyloid (Aβ) accumulation.
- PARP16, a Poly(ADP-ribose) polymerase, is an ER transmembrane protein involved in ER stress.
- PARP16 levels are elevated in AD models, suggesting a role in disease progression.
Purpose of the Study:
- To investigate the role of PARP16 in Alzheimer's disease pathogenesis.
- To determine the effect of PARP16 on cognitive function, amyloid burden, and neuroinflammation in AD.
Main Methods:
- Utilized APPswe/PS1dE9 (APP/PS1) mice and HT22 cells exposed to Aβ.
- Employed adeno-associated virus (AAV)-mediated PARP16 knockdown in APP/PS1 mice.
- Assessed spatial memory using the Morris water maze test.
- Analyzed amyloid deposition, neuronal apoptosis, and inflammatory cytokine production.
- Conducted in vitro experiments to evaluate neuronal damage and ER stress.
Main Results:
- PARP16 expression was significantly increased in AD mouse brains and Aβ-treated cells.
- PARP16 knockdown in APP/PS1 mice partially rescued spatial memory deficits.
- Reduced amyloid deposition, neuronal apoptosis, and neuroinflammation were observed following PARP16 knockdown.
- In vitro, PARP16 knockdown mitigated Aβ-induced neuronal damage and ER stress.
- PARP16 was identified as an RNA-binding protein that enhances amyloid precursor protein (APP) mRNA stability.
Conclusions:
- PARP16 plays a significant, previously unrecognized role in Alzheimer's disease pathogenesis.
- PARP16 contributes to AD pathology by increasing APP mRNA stability and subsequent APP levels.
- Targeting PARP16 may offer a therapeutic strategy for Alzheimer's disease.
More Related Videos
06:44Quantitative Analysis of Mitochondria-Associated Endoplasmic Reticulum Membrane (MAM) Stabilization in a Neural Model of Alzheimer's Disease (AD)
Published on: January 10, 2025
15:23Selection of Aptamers for Amyloid β-Protein, the Causative Agent of Alzheimer's Disease
Published on: May 13, 2010
Related Concept Videos
Amyloid Fibrils
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
mRNA Stability and Gene Expression
Cis-acting Elements involved in mRNA stability
Abnormal Proliferation
The Unfolded Protein Response
Nonsense-mediated mRNA Decay
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...